2020
DOI: 10.1002/npr2.12142
|View full text |Cite
|
Sign up to set email alerts
|

Non‐24‐hour sleep‐wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 26 publications
(59 reference statements)
0
3
0
Order By: Relevance
“…As previously reported, our case confirms that they might be affected by non‐24‐h sleep–wake disorder. Melatonin (or agonist) is efficacious and safe for long‐term treatment in ASD and CRSWD, including in children, with light therapy and wakefulness promoting medication (Auger et al, 2015; Iwata & Kaneko, 2020; Maras et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…As previously reported, our case confirms that they might be affected by non‐24‐h sleep–wake disorder. Melatonin (or agonist) is efficacious and safe for long‐term treatment in ASD and CRSWD, including in children, with light therapy and wakefulness promoting medication (Auger et al, 2015; Iwata & Kaneko, 2020; Maras et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…Excess orexin signaling with decreased REM sleep has been observed in an animal model of one NDD, Tuberous Sclerosis Complex, which was rescued by DORA treatment [ 9 ]. However, there is little clinical safety and efficacy data on the use of DORAs in the pediatric population [ 10 ] or in NDDs specifically [ 11 , 12 ] (Table 1 ).…”
Section: Introductionmentioning
confidence: 99%
“…[ 10 ] 30 (10–20) 20 mg Insomnia Mix of comorbid psychiatric disorders; seven patients with ASD No significant difference in sleep between those who stayed on suvorexant and those who discontinued it Two patients with nightmares Oka et al . [ 11 ] 3 (13–19) 15-20 mg Circadian rhythm sleep–wake disorders Two patients with ASD One fell asleep two hours earlier, one had sleep phase advance two hours, one had a fixed nocturnal sleep schedule None reported Iwata et al [ 12 ] 1 (23) 15 mg Non-24-h sleep–wake disorder ASD Sleep rhythm restoration* None reported Prieto et al . [ 14 ] 1 (16) 10 mg Insomnia Bipolar disorder Sleep duration improved from 3–4 to 6–7 h per night, sleep quality improved, and the patient reported more refreshing sleep None reported *Treatment in combination with ramelteon, ASD Autism spectrum disorder, mg milligrams, N number of patients …”
Section: Introductionmentioning
confidence: 99%